Pharmafile Logo
Pharmafocus logo
Advanced Search

Eylea

Showing 15 posts of 39 posts found.

Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration

February 18, 2020
Manufacturing and Production, Sales and Marketing Beovu, Eylea, Novartis, Regeneron, macular degeneration, pharma

The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet …

News

Bayer’s Eylea shows strong vision benefits across two regimens in post-marketing study

February 5, 2020
Research and Development Bayer, Eylea, pharma

Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment …

News
novartis_outside_1

FDA approves Novartis’ Beovu injection for wet age-related macular degeneration

October 8, 2019
Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma

Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …

News
ipos0_l

FDA expands indication for Eylea to cover all stages of diabetic retinopathy

May 14, 2019
Manufacturing and Production Bayer, Eylea, FDA, Regeneron, approval, pharma

The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy. Regeneron chief scientific …

News

Courts back NHS in fight against Novartis and Bayer

September 24, 2018
Sales and Marketing Bayer, Eylea, NHS, Novartis, avastin, ludentis

The NHS has won a court case against multinational pharmaceutical firms Novartis and Bayer, after the companies sought to block …

News
ipos0_l

Regeneron’s Eylea wins FDA approval for wet age-related macular degeneration

August 20, 2018
Sales and Marketing Bayer, Eylea, FDA, Regeneron, US, pharma

Regeneron is celebrating the approval in the US of its vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for the …

News
regeneron

Regeneron’s Eylea smashes Phase 3 trial goal in diabetic retinopathy

March 20, 2018
Manufacturing and Production, Research and Development Eylea, Regeneron, diabetes, pharma

Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection Eylea (aflibercept) met its primary endpoint in a …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

News
regeneron

Reports increasing of worrying side-effects with Regeneron’s Eylea

February 22, 2018
Medical Communications, Research and Development, Sales and Marketing Eylea, FDA, Regeneron, pharma

Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …

News
eylea-product-box-md

Regeneron forced to drop Eylea combo, advantage Novartis

November 27, 2017
Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron, biotech, drugs, pharma, pharmaceutical

Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a …

News

NICE recommends Bayer’s Eylea for myopic chorodial neovascularisation

September 22, 2017
Medical Communications, Sales and Marketing Bayer, Eylea, NICE, pharma, pharmaceutical

Bayer has revealed that UK drug regulator NICE has given its final recommendation on blockbuster eye drug Eylea (aflibercept solution …

News

Novartis receives positive news in eye drug P3 studies

June 20, 2017
Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron

Novartis has achieved positive feedback from its two Phase 3 studies into its eye drug RTH258 (brolucizumab), which found it …

News
eylea-product-box-md

Regeneron’s Eylea fails combination study endpoint

October 3, 2016
Research and Development, Sales and Marketing Eylea, Regeneron

Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …

News
eylea-product-box-md

NICE approves Bayer’s Eylea for NHS use

September 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE

Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …

News
eylea-product-box-md

NICE recommends Eylea as first-line treatment for sight threatening condition

August 24, 2016
Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment

Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024